

from methanol and dried in vacuo to give 77 mg (19%) of 1-¹³C, mp 225–227 °C dec. Authentic unlabeled 1 had mp 226–227 °C dec.

In a similar manner 366 mg (1.56 mmol) of 2 and 199 mg (1.67 mmol) of 5-¹⁴C in 1.70 mL of methanol gave, after recrystallization, 194 mg (51%) of 1-¹⁴C, mp 224–226 °C dec.

The title compounds were characterized by their infrared spectra [(KBr) 3400, 1685, 1495, and 1100 cm⁻¹] which were identical with that of authentic, unlabeled 1, except minor differences in 1-6-¹³C due to the high percentage of isotope composition. These compounds were also characterized by the GC retention time of their Me₃Si derivatives from reaction with *N,O*-bis(trimethylsilyl)trifluoroacetamide in acetonitrile on column a at 250 °C, which were identical with that of Me₃Si-1, and by the mass spectra of their Me₃Si derivatives. The latter gave major fragments at *m/e* (rel intensity) 245 (36), 217 (98), 147 (49), and 73 (100), as were the major ions of Me₃Si-1. No major ion contained the ¹³C label. The ¹³C NMR spectrum of 1 using natural ¹³C abundance has been published.¹³ Synthetic 1-¹³C (0.15 M in H₂O–D₂O) showed a single chemical shift of 157.5 ppm for C-6 relative to Me₄Si (lit.¹³ 157.5 ppm).

Drug Analysis. Thin-layer chromatographic separation of 1 from metabolites was performed by a modified published procedure.⁶ Known volumes of biological fluids from radiolabeled 1-treated rabbits along with standards of 1 spiked into blank bile and urine were applied onto Eastman cellulose sheets (Rochester, N.Y.) which were subsequently developed in a solvent system consisting of isobutyric acid–triethylamine–water, 66:2:32. Visible spots under UV lamp (UV SL-25, San Gabriel, Calif.) corresponding to the *R_f* of 1 (0.72) were sectioned and transferred into liquid scintillation vials. In the case of low concentrations of 1 in the biological samples, a small amount of unlabeled 1 was added to increase visibility, and the spots were processed as before. These TLC materials were assayed for radioactivity using a standard liquid scintillation counting procedure with a Beckman 300 (Beckman, Fullerton, Calif.) liquid scintillation counter. The UV visible spots corresponding to 1 without isotopic dilution were

pooled and the specific activity was examined via absorption at 254 nm and liquid scintillation counting. Comparable specific activity to the administered dose of 1 validated the TLC analysis.

Acknowledgment. The combined financial support by LAC/USC Cancer Center Grant Unit 5, P01-CA14089-2, and by Western Cancer Study Group Grant SR05 CA05186-13, Pharmacokinetic Section, is greatly appreciated.

References and Notes

- (1) A. J. Weiss, J. E. Stambaugh, M. J. Mastrangelo, J. F. Laucius, and R. E. Bellet, *Cancer Chemother. Rep.*, **56**, 413 (1972).
- (2) R. Bellet, P. Engstrom, and J. Yarbrow, *Clin. Res.*, **19**, 736 (1971).
- (3) M. Karon, L. Sieger, and S. Leimbrock, *Proc. Am. Assoc. Cancer Res.*, **14**, 94 (1973).
- (4) M. Karon, L. Sieger, and S. Leimbrock, *Blood*, **42**, 359 (1973).
- (5) K. B. McCredie, G. P. Bodey, and M. A. Burgess, *Blood*, **40**, 975 (1972).
- (6) P. Pithova, A. Piskala, J. Pitha, and F. Sorm, *Collect. Czech. Chem. Commun.*, **30**, 2801 (1965).
- (7) R. E. Notari and J. L. De Young, *J. Pharm. Sci.*, **64**, 1148 (1975).
- (8) K. Raska, Jr., M. Jurovcik, Z. Sormova, and F. Sorm, *Collect. Czech. Chem. Commun.*, **30**, 3370 (1965).
- (9) G. L. Neil, R. E. Moxley, S. L. Kuentzel, R. C. Manak, and L. J. Hanka, *Cancer Chemother. Rep.*, **59**, 459 (1975).
- (10) M. Jurovcik, K. Raska, Jr., Z. Sormova, and F. Sorm, *Collect. Czech. Chem. Commun.*, **30**, 3370 (1965).
- (11) K. Veres, J. Kozel, and Z. Prochazka, *Collect. Czech. Chem. Commun.*, **28**, 750 (1963).
- (12) Z. Arnold and M. Kornilov, *Collect. Czech. Chem. Commun.*, **29**, 645 (1964).
- (13) A. J. Jones, D. M. Grant, M. W. Winkley, and R. K. Robins, *J. Phys. Chem.*, **74**, 2684 (1970).

Synthesis of Some Conformationally Restricted Analogues of Fentanyl¹

Joel G. Berger,*

Department of Medicinal Chemistry, Endo Labs, Inc., Garden City, New York 11530

Fredric Davidson,

Central Research & Development Department, E. I. du Pont de Nemours and Co., Inc., Wilmington, Delaware 19898


and Gordon E. Langford

Searle Chemistry Laboratory, Department of Chemistry, The University of Chicago, Chicago, Illinois 60637.

Received June 23, 1976

The preparation of *cis*- and *trans*-2,3,4,4a,5,9b-hexahydro-2-phenethyl-5-propionyl-1*H*-pyrido[4,3-*b*]indole is described. These compounds, which are conformationally restricted analogues of the potent analgesic fentanyl, were devoid of analgesic or CNS activity.

The 4-anilidopiperidines 1 as archetypified by fentanyl (R = CH₂CH₂C₆H₅; R₁ = C₂H₅; R₂ = H) have been shown to constitute a class of extremely potent short-acting morphine-like analgesics.² Previous efforts in delineating




the structure–activity relationships in this series have

focused on varying the nature and stereochemical relationships of the substituents R, R₁,^{2,3} and R₂.⁴ Most recently,⁵ R₁ has been tied back to the ortho position of the aromatic ring.

The 4-anilidopiperidines are conformationally mobile, although recent ¹H NMR data suggest that the preferred conformers are piperidine chairs with the anilido group equatorially oriented.³ In view of the nature of the previous studies, it was felt to be of interest to prepare some analogues of fentanyl where conformational mobility is restricted and to assess the effect of this upon biological activity.

Treatment of 2 with sodium cyanoborohydride in trifluoroacetic acid⁶ gave 3 (Scheme I). Reaction of 2 with BH₃–THF followed by treatment with 37% HCl and

Scheme I

Table I. ^{13}C Chemical Shifts (ppm from Me_4Si) in CDCl_3

Compd	C-4a	C-9b
3	57.5	41.1
4	58.8	40.7
5	68.4	47.3
6	69.3	47.4

subsequent neutralization gave the diastereomeric **5**. Propionylation yielded **4** and **6**, respectively.



Although previous work in these laboratories has established that the BH_3 reduction procedure applied to compounds closely related to **2** gives rise to the trans-ring junction,⁷ the configurational assignments can be unequivocally confirmed by means of ^{13}C NMR. Thus, the signals for C-4a and C-9b are shifted to much higher field in **3** and **4** as compared to **5** and **6** (Table I). This effect has been previously observed in the diastereomeric decalins⁸ and decahydroquinolines⁹ and is presumed due to γ -gauche interactions in the cis isomers.

The trans-ring junction demands a completely rigid "locked" conformation for compounds **5** and **6** in which the substituents on the piperidine ring are fused diequatorially. Therefore, **6** represents a conformationally fixed fentanyl. Cis compounds **3** and **4**, however, are conformationally mobile and may exist as conformers **7a-d** (Scheme II).

The 220-MHz ^1H NMR spectrum of **3** shows signals assigned to H-4a at δ 3.80 and 3.21 assigned to H-9b as doublets of triplets. By application of the INDORE¹⁰ technique at 270 MHz, coupling constants for each proton on the piperidine ring may be unequivocally assigned (Table II).

These data appear uniquely interpretable in terms of conformation **7d**. The situation for **4**, however, is quite different. At 220 MHz at $+68^\circ\text{C}$, H-4a is observed at δ 4.43 as a quartet (line separations 8 Hz) of 24 Hz band-

Scheme II

Table II. Coupling Constants for Compound **3** (± 0.5 Hz)

J	Hz	J	Hz
4a,9b	6.6	4ax,4eq	-13.8
4a,4ax	5.0	4ax,3ax	10.5
4a,4eq	4.0	4ax,3eq	5.0
9b,lax	9.7	4eq,3ax	3.3
9b,leq	6.3	4eq,3eq	4.5
lax,leq	-11.5	3ax,3eq	-11.0

width and H-9b as a distorted triplet, bandwidth 15 Hz, at δ 3.42. These ^1H NMR assignments were confirmed by single-frequency proton decoupling of the ^{13}C NMR spectrum. The observed bandwidths are well accounted for by conformation **7a**, and the data closely parallel that recently reported for *N*-acetyl-*cis*-hexahydrocarbazole.¹¹ The twist-boat conformer **7b** may be ruled out in view of the narrow bandwidth of H-9b. It therefore seems that **4** is also conformationally analogous to fentanyl in that the anilido nitrogen is equatorial to a chair piperidine.

Both **4** and **6**·HCl were inactive in the mouse phenylquinone writhing test¹² at doses of up to 130 mg/kg orally. Fentanyl was found to have an ED_{50} of 0.8 mg/kg in the same test at a peak time of 10 min after oral dosing. In addition, **4** and **6**·HCl showed no depression of locomotor activity (visual) in the mouse at doses up to 200 mg/kg orally.

In view of these results, it is tempting to conclude that analgesic activity in the fentanyl series is highly dependent on stereochemical factors. However, it should be kept in mind that differences in absorption, distribution, and metabolism may exist between these two series and may play an important role.

Experimental Section

Melting points were determined in open capillary tubes and are uncorrected. ^1H NMR spectra were determined on a Varian HR-220 spectrometer and on the Bruker HF-270 spectrometer at The University of Chicago. ^{13}C spectra were determined using a Bruker WH-90 spectrometer. IR spectra were recorded using a Perkin-Elmer 727 spectrometer. Analytical results were within $\pm 0.4\%$ of theory for the elements stated (Spang Microanalytical Lab, Ann Arbor, Mich.).

Compounds tested were administered as solutions or suspensions in 1% aqueous Methocel.

cis-2,3,4,4a,5,9b-Hexahydro-2-phenethyl-1H-pyrido[4,3-b]indole (**3**). A freshly prepared solution of $\text{Na}(\text{CN})\text{BH}_3$ (10.0 g, 0.16 mol) in 25 mL of methanol was added dropwise to a stirred solution of **2**¹³ (9.0 g, 0.032 mol) in 100 mL of $\text{CF}_3\text{CO}_2\text{H}$ at ice-bath temperature under a nitrogen atmosphere. Vigorous gas evolution resulted. Upon completion of the addition, the reaction mixture was stirred at room temperature for 1 h and then poured into 400 mL of water. The resulting mixture was stirred 15–20 min and

basified with 50% NaOH and the resulting mixture extracted twice with 200-mL portions of ether. The combined extracts were washed once with water and then extracted twice with 100-mL portions of 6 N HCl. The extracts were basified, and the oily product was reextracted into ether. After washing with water and drying over anhydrous K_2CO_3 , the filtered solution was evaporated in vacuo to yield crude **3** (7.4 g) as a pale yellow oil which was distilled in a Kugelrohr apparatus. Two fractions were taken: bp 170–175 °C (bath) (0.05 mm) (3.7 g) and bp 147–153 °C (bath) (0.01 mm) (1.6 g). Both fractions were colorless viscous oils which crystallized on trituration with pentane: mp 70–71 °C; infrared (Nujol) 3350 cm^{-1} (NH); TLC R_f 0.53 (silica gel F_{254} ; eluent, 8% Et_2NH in benzene). Anal. ($C_{19}H_{22}N_2$) C, H, N.

cis-**2,3,4,4a,5,9b-Hexahydro-2-phenethyl-5-propionyl-1H-pyrido[4,3-b]indole (4)**. A solution of propionyl chloride (2.0 mL, 2.1 g, 0.023 mol) in 10 mL of $CHCl_3$ was added dropwise to a stirred solution of **3** (4.4 g, 0.016 mol) and triethylamine (3.5 mL, 0.025 mol) in 75 mL of $CHCl_3$. The reaction mixture was heated at reflux for 30 min, cooled, and washed twice with water. After drying over anhydrous K_2CO_3 , evaporation in vacuo left a yellow oil which deposited crystals (3.4 g) from benzene–hexane: mp 105–108 °C. Recrystallization from ethanol gave pure **4** (2.1 g, 27% yield): mp 109–110 °C; infrared (Nujol) 1660 cm^{-1} (amide C=O).

trans-**2,3,4,4a,5,9b-Hexahydro-2-phenethyl-1H-pyrido[4,3-b]indole (5)**. A warm solution of **2** (34.5 g, 0.125 mol) in 300 mL of dioxane was added dropwise to 500 mL of a stirred solution of 1 M BH_3 in THF (Alfa-Ventron) under a nitrogen atmosphere. Vigorous gas evolution was noted during addition. The resulting mixture was then heated at reflux for 3.5 h and then THF was slowly distilled from the mixture and replaced with dioxane until a pot temperature of 96 °C was attained. The resulting mixture was maintained at reflux overnight, then cooled in ice, and cautiously decomposed by addition of 300 mL of 37% HCl. The resulting mixture was heated at reflux for 2 h, cooled, and basified with excess 50% NaOH solution. Most of the volatile solvent was removed on a rotary evaporator, and the residue was then diluted with water to dissolve inorganic salts. It was then extracted with two 250-mL portions of ether, and the combined extracts were then washed with water and in turn extracted with two 250-mL portions of 3 N HCl. The combined acid extracts were washed once with ether and basified, and the precipitated oil was reextracted into ether. The ether solution was dried over anhydrous K_2CO_3 , filtered, and evaporated in vacuo to give a solid product which was recrystallized twice from ether–hexane–benzene to give 15.2 g (44%) of **5**: mp 105–107 °C; infrared (Nujol) 3300 cm^{-1} (NH); TLC R_f 0.49 (silica gel F_{254} , 8% Et_2NH in benzene). Anal. ($C_{19}H_{22}N_2$) C, H, N.

trans-**2,3,4,4a,5,9b-Hexahydro-2-phenethyl-5-propionyl-1H-pyrido[4,3-b]indole (6)**. Compound **5** (5.6 g, 0.02 mol) was propionylated in a manner identical with that used to prepare **4**. The crude product was obtained as a waxy solid which was taken up in 75 mL of ethanol and treated with dry HCl. On chilling a solid (3.5 g) separated which was filtered and recrystallized from 125 mL of H_2O to give 2.8 g (38%) of **6**·HCl: mp 280–282 °C dec. Anal. ($C_{22}H_{26}N_2O \cdot HCl$) C, H, N, Cl.

The mother liquor from the above recrystallization was basified with 1 N NaOH and the precipitated oil extracted into ether. After drying over anhydrous K_2CO_3 and evaporation in vacuo, a yellow oil was obtained which was dissolved in 50 mL of pentane and allowed to stand overnight at 0–5 °C. The white crystals which formed were filtered and dried to give 0.25 g of free base: mp 96–98 °C; mmp with **4**, 86–100 °C; infrared (Nujol) 1660 cm^{-1} (amide C=O); 1H NMR (270 MHz, $CDCl_3$) δ 1.29 (t, $J = 6$ Hz, 3 H, CH_3), 2.10 [q ($J = 12.3$ Hz) of d ($J = 4.0$ Hz), 1 H, H-4ax], 2.57 (q, $J = 6$ Hz, 2 H, $CHCH_3$), 2.71–2.93 (m, 5 H, overlapping H-3ax and CH_2CH_2), 3.13 [t ($J = 12.3$ Hz) of d ($J = 2.0$ Hz), 1 H, H-9b], 3.25 (d, $J = 11.8$ Hz, 1 H, H-3eq), 3.48 [t ($J = 14.7$ Hz) of d ($J = 4.0$ Hz), 1 H, H-4a], 3.60 [d ($J = 12.0$ Hz) of d ($J = 2.5$ Hz), 1 H, H-1eq]. Anal. ($C_{22}H_{26}N_2O$) C, H, N.

Acknowledgment. We wish to thank Dr. D. H. Smith, Stine Laboratory, E. I. du Pont de Nemours, Inc., Newark Del., Dr. M. Cohen, Mr. H. Dayton, and Ms. M. MacDonald, Endo Laboratories, Inc., Garden City, N.Y., for pharmacological results. G.E.L. thanks the National Research Council of Canada for a postdoctoral fellowship.

References and Notes

- Contribution No. 111 from Endo Laboratories, Inc. (subsidiary of E. I. du Pont de Nemours and Co.).
- P. A. J. Janssen and C. A. M. Van der Eycken in "Drugs Affecting the Central Nervous System", A. Burger, Ed., Marcel Dekker, New York, N.Y., 1968, pp 51–54, and ref 72 cited therein.
- A. F. Casey, M. M. A. Hassan, A. B. Simonds, and D. Staniforth, *J. Pharm. Pharmacol.*, **21**, 434 (1969).
- T. N. Riley, D. B. Hale, and M. C. Wilson, *J. Pharm. Sci.*, **62**, 983 (1973); W. F. M. Van Bever, C. J. E. Niemegeers, and P. A. J. Janssen, *J. Med. Chem.*, **17**, 1047 (1974).
- W. Klein, W. Bach, and E. Mutschler, *Arch. Pharm. (Weinheim, Ger.)*, **308**, 910 (1975).
- G. W. Gribble, P. D. Lord, J. Skotnicki, S. E. Dietz, J. E. Eaton, and J. L. Johnson, *J. Am. Chem. Soc.*, **96**, 7812 (1974).
- J. G. Berger, S. R. Teller, C. D. Adams, and L. F. Guggenberger, *Tetrahedron Lett.*, 1807 (1975).
- E. Lippmaa and T. Pehk, *Eesti NSV Tead. Akad. Toim., Keem., Geol.*, **17**, 287 (1968) [*Chem. Abstr.*, **69**, 111944e (1968)].
- H. Booth and D. V. Griffiths, *J. Chem. Soc., Perkin Trans. 2*, 842 (1973).
- V. J. Kowalewski, *Prog. Nucl. Magn. Reson. Spectros.*, **5**, 1 (1969).
- H. Booth and T. Masamune, *J. Chem. Soc., Perkin Trans. 2*, 354 (1972).
- F. Siegmund, R. Cadmus, and G. Lu, *Proc. Soc. Exp. Biol. Med.*, **95**, 729 (1957).
- R. G. W. Spickett, *J. Med. Chem.*, **9**, 436 (1966).

Synthesis of Some Pentazocine Metabolites and Related Compounds

Noel F. Albertson* and Frank C. McKay

Sterling-Winthrop Research Institute, Rensselaer, New York 12144. Received July 6, 1976

The syntheses of the *trans* alcohol **2** and the *trans* acid **5**, metabolites of pentazocine (**1**), are described. These are essentially devoid of agonist and antagonist activities. Some related oxidation products were also prepared for comparison with products isolated during metabolism studies.

Early studies of the metabolism of pentazocine (**1**) in this Institute by Rosi and Merola¹ using mouse liver homogenates led to the isolation of a sufficient amount of the major metabolite as the acetate derivative to characterize by NMR. The data (see Experimental Section) showed that there was a loss of a side-chain methyl signal

from pentazocine and the gain of a CH_2OAc group so that the compound was the acetate of either **2** or **3**, but in the absence of a sample of known configuration, no decision could be reached as to whether the *cis* alcohol **3** or *trans* alcohol **2** had been isolated. The present work was undertaken to provide a reference sample for comparison so